Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

About this update from Bolt Biotherapeutics, Inc.

[{"type":"image","alt":"Bolt Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Bolt Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/7c034fa4294bd392e965b4cf4a9ef25c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIPaI3UaLPpJb6VD5RYb0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTk0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7c034fa4294bd392e965b4cf4a9ef25c","width":166,"height":74}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":240,"olType":false},{"type":"text","content":"REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update.","length":330,"tagName":"p"},{"type":"text","content":"“BDC-4182 is the first of our next-generation Boltbody™ ISACs to enter the clinic, and we saw a clear difference versus our first-gen ISACs in terms of immune response from the very first patient treated,” said Willie Quinn, President and Chief Executive Officer. “The ISAC mechanism is radically different from ADCs and T cell engagers, and we believe that demonstrating anti-tumor activity with BDC-4182 will unlock an entirely new approach to treating cancer. We continue to enroll patients with gastric and gastroesophageal cancers in the Phase 1 dose-escalation trial and remain on track to report initial data in the third quarter of 2026.”","length":646,"tagName":"p"},{"type":"text","content":"Recent Highlights and Anticipated Milestones ","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Initial clinical data from BDC-4182 Phase 1 study for patients with gastric and gastroesophageal cancer expected in the third quarter of 2026. BDC-...

More updates from Bolt Biotherapeutics, Inc.